Sign up USA
Proactive Investors - Run By Investors For Investors

Bristol-Myers Squibb to get keys to Padlock

Bristol-Myers Squibb Company is to snap up Padlock Therapeutics
Bristol-Myers Squibb to get keys to Padlock
Bristol-Myers Squibb to buy Padlock

Bristol-Myers Squibb Company (NYSE:BMY) is to snap up Padlock Therapeutics, it was announced on Wednesday.

The companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.

The acquisition will give Bristol-Myers Squibb full rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis (RA).

Padlock’s PAD discovery programme may have additional utility in treating systemic lupus erythematosus (SLE) and other autoimmune diseases.

Bristol-Myers shares closed down 0.73% at $62.34.



Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Related Articles

1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
AZN3.jpg
March 23 2016
Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC